Bio-Bridge Science to Relocate Headquarters to Oakbrook Terrace, Illinois, USA
July 08 2010 - 3:31PM
Business Wire
Bio-Bridge Science, Inc. (OTCBB: BGES), a biotechnology company
engaged in the commercial development of biological products for
the prevention and treatment of human diseases and manufacturing
and sales of materials used during vaccine production, announced
today that it plans to move its corporate headquarters from Oak
Brook, Illinois to the neighboring City of Oakbrook Terrace,
Illinois by September 2010. The new location offers the company an
increase in office space, a significant reduction in cost per
square foot, and greater flexibility in space requirements and
utilization.
“This decision reflects our need to be able to expand or adapt
to changes in our business while maintaining costs at a reasonable
level. We have enjoyed our time in Oak Brook; however, the
objective is to increase our office space while reducing the cost
per square foot and we felt Oakbrook Terrace met this objective
better,” said Dr. Liang Qiao, CEO.
About Bio-Bridge Science
Bio-Bridge Science is currently developing products including an
HIV vaccine, a colon cancer therapeutic vaccine, and an HPV
vaccine. Additionally, the company sells bovine serum, a material
used in vaccine production through its subsidiary, Bio-Bridge
Xinheng Baide Biotechnology. The Company's 51% owned joint venture,
Bio-Bridge JRS Biosciences, will produce cell-culture medium which
is also a material used in vaccine production. For more information
please visit http://www.bio-bridge-science.com/.
Forward-Looking Statements
This press release contains forward-looking statements.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. These statements are subject to
uncertainties and risks including, but not limited to, product and
service demand and acceptance, changes in technology, economic
conditions, the impact of competition and pricing, government
regulation, and other risks defined in this document and in
statements filed from time to time with the Securities and Exchange
Commission. All such forward-looking statements, whether written or
oral, and whether made by or on behalf of the company, are
expressly qualified by these cautionary statements and any other
cautionary statements which may accompany the forward-looking
statements. In addition, the company disclaims any obligation to
update any forward-looking statements to reflect events or
circumstances after the date hereof. Please refer to the Company's
SEC filings for additional information.
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jul 2023 to Jul 2024